Esperion Therapeutics Dividend
Dividend criteria checks 0/6
Esperion Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.4% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$1.10 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Feb 28Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Jan 22Esperion Is Sitting On A Potential Blockbuster Drug
Jan 14Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Jun 19
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Mar 09Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%
Feb 23Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol
Aug 26Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Aug 09Esperion Therapeutics Q2 2022 Earnings Preview
Aug 01Esperion Therapeutics: 2021 Labors Paying Off In 2022
May 07Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout
Feb 24Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022
Jan 20Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection
Oct 27Esperion: Hunting Big Game In The Danger Zone
Aug 05Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year
May 09Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 04Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.
Dividend Yield vs Market
| Esperion Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ESPR) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast in 3 Years (ESPR) | 0% |
Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ESPR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ESPR has not reported any payouts.